Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II intravenous CNTO328 in recurrent epithelial ovarian cancer
2006-005704-13Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siltuximab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Queen Mary University of London. Primary endpoints: Any response, CT-based disease response and 2 more. Started Mar 2007; status: completed.
02
Drugs
siltuximab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2006-005704-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005704-13.